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Background: Paxillin (PXN) has been found to be aberrantly regulated in various malignancies and involved in
tumor growth and invasion. The clinicopathological and prognostic significance of PXN in gastric cancer is still
unclear.
Methods: The expression of PXN was determined in paired gastric cancer tissues and adjacent normal tissues by
Western blotting and real-time PCR. Immunohistochemistry was performed to detect the expression of PXN in 239
gastric cancer patients. Statistical analysis was applied to investigate the correlation between PXN expression and
clinicopathological characteristics and prognosis in patients. Additionally, the effects of PXN on gastric cancer cell
proliferation and migration were also evaluated.
Results: PXN was up-regulated in gastric cancer tissues and cell lines as compared with adjacent normal tissues
and normal gastric epithelial cell line GES-1. Overexpression of PXN was correlated with distant metastasis (P = 0.001)
and advanced tumor stage (P = 0.021) in gastric cancer patients. Patients with high PXN expression tended to have
poor prognosis compared with patients with low PXN expression (P < 0.001). Multivariate analysis demonstrated that
PXN expression was an independent prognostic factor (P = 0.020). Moreover, ectopic expression of PXN promotes cell
proliferation and migration in AGS cells whereas knockdown of PXN inhibits cell proliferation and migration in SGC7901
cells.
Conclusions: PXN plays an important role in tumor progression and may be used as a potential prognostic indicator in
gastric cancer.
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Gastric cancer is among the most frequently diagnosed
cancer and the second leading cause of cancer-related
mortality worldwide [1,2]. In spite of recent improvement
in the clinical treatment of gastric cancer, patients with ad-
vanced stage of gastric cancer still have poor survival.* Correspondence: xurh@sysucc.org.cn
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reproduction in any medium, provided the orSurgical resection is still the only curative therapy available
for this disease [3]. Under this circumstance, there is an
urgent need to better understand the biological mechan-
ism of this neoplasm so as to guide patient management
and develop novel therapeutic strategies.
The paxillin (PXN) gene was first identified as a
tyrosine-containing protein in cells transformed by the
src oncogene [4] and encodes for a focal adhesion mol-
ecule of 68 kD [5]. PXN functions as an adaptor protein
that coordinates multiple signals from integrins, growth
factors and cell surface receptors [6]. By these protein-
protein interactions, PXN regulates diverse physiological
process, such as gene expression, matrix organization,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ity and metastasis [6-8]. In addition to the interactions
with cytoskeleton proteins, PXN could also bind to several
oncogenic proteins, such as v-Src, E6 and BCR-ABL
[9-13]. Such proteins could use PXN as a docking site or
as a substrate to interrupt or mislead the normal adhesion
and growth factor signaling pathways that are essential for
controlled cellular growth and migration [5]. PXN has
been found to be involved in many tumor types. A previ-
ous study reported that PXN could inhibit lung cancer
proliferation and motility [14]. However, more recent
studies found PXN was overexpressed and acted as an
pro-oncogene in a variety of tumors, including non-small
cell lung cancer, colorectal cancer, prostate cancer and cer-
vical carcinoma [15-20]. In gastric cancer, Li et al. re-
ported that PXN (tyr118) phosphorylation was a key
factor for fibronectin-stimulated invasiveness of AGS cells
[21]. However, the clinicopathological and prognostic role
of PXN in gastric cancer is still unclear.
In this study, we detected the PXN mRNA and protein
level in 30 paired tumor tissues and adjacent normal tis-
sues and found that PXN was frequently up-regulated in
tumor tissues. In addition, the expression of PXN was
associated with poor prognosis in a large cohort of 239
patients. Furthermore, ectopic expression/knockdown of
PXN could promote/inhibit cell proliferation and migra-
tion in gastric cancer cells.
Materials and methods
Human tissue specimens and cell lines
This study was approved by the ethics committee of Sun
Yat -sen University Cancer Center and written informed
consents for using the samples for research purpose were
obtained from all the patients before surgery. We collected
239 paraffin-embedded, archived tissue samples from pa-
tients who underwent surgery in Sun Yat-sen University
Cancer Center (Guangzhou, China) from 2004 to 2008.
Moreover, we obtained paired fresh gastric cancer tissues
and adjacent nontumorous tissues from 30 of the 239 pa-
tients and kept in liquid nitrogen until use. All the patients
had a histologically confirmed diagnosis of gastric cancer
after resection. Tumor stage was determined according to
the 7th edition of the International Union Against Cancer
(UICC) on Tumor-Node-Metastasis (TNM) staging sys-
tem. All the patients were followed-up regularly every
three months after surgery with a median follow-up time
of 32.5 months (range from 4 to 75 months). All the pa-
tients did not receive any pre-operative treatment. The pa-
tients who received adjuvant chemotherapy after surgery
were based on 5-FU, platinum or taxol regimens. Relevant
clinicopathological information including age, gender,
tumor size, tumor depth, lymph node invasion, distant
metastasis, differentiation status, TNM stage and treat-
ment strategies were obtained from patients’ medical files.The human gastric cancer cell lines HGC27, SGC7901,
BGC823, AGS and MKN28 were obtained from either the
RIKEN Cell Bank or the American Type Culture Collec-
tion and were cultured with RPMI 1640 medium (GIBCO,
Carlsbad, CA, USA) containing 10% fetal bovine serum
(FBS, invitrogen, Carlsbad, CA, USA) in a humidified
chamber with 5% CO2 at 37°C. Human gastric epithelial
cell line GES-1 was purchased from the Cell Bank of
Chinese Academy of Sciences (Shanghai, China) and
was cultured with Dulbecco’s Modified Eagle Medium
(GIBCO, Carlsbad, CA, USA) supplemented with 10%
FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml).
RNA extraction and real-time quantitative RT-PCR analysis
Total RNA was extracted from the tissues or cells using
Trizol reagent (Invitrogen, Carlsbad, CA, USA) and
complementary DNA (cDNA) was synthesized with 2 μg
of total RNA by using M-MLV transcriptase (Promega,
Madison, WI). Real-time PCR was performed with an
ABI PRISM® 7500 Fast Real-time PCR System (Applied
Biosystems, CA, USA) and a SYBR Premix Ex Taq™ kit
(Takara, Japan); β-actin expression was used as a refer-
ence. The following temperature profiles were used: ini-
tial heating at 95°C for 10 min, followed by 45 cycles of
denaturation at 95°C for 10 s, annealing at 60°C for 10 s,





Data were analyzed using the 2-△△ct method.
Western blot analysis
Total cellular proteins were extracted from tissues or cells
and separated by SDS-PAGE gels, Western blot analysis
was performed according to a standard method as previ-
ously described [22]. For immunoblotting of PXN, a rabbit
PXN antibody (1:1000, Cell Signaling Technology, USA)
was used, and an anti-GAPDH antibody (1:2000; Santa
Cruz Biotechnology, USA) was used as loading control.
Immunohistochemistry (IHC) analysis
IHC analysis of PXN was performed according to a pre-
viously described method [23]. Briefly, the formalin-
fixed, paraffin-embedded tissue samples were cut into
4 μm slides, dewaxed in xylene, rehydrated with graded
of alcohols, and then treated with 3% hydrogen peroxide
to block endogenous peroxidase activity. The slides were
boiled in 0.01 mol/L sodium citrate buffer (pH 6.0) in a
microwave oven to retrieve tissue antigens. Tissue sam-
ples were pretreated with 10% normal goat serum to in-
hibit non-specific staining and incubated at 4°C with a
primary antibody (ab#32084, abcam) over night. Tissue
sections were then washed with PBST, treated with an
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din horseradish peroxidase complex, and finally devel-
oped using diaminobenzidine tetrahydrochloride (DAB).
To assess the expression of PXN, we qualified and
scored both the extent and intensity of immunoreactiv-
ity. In this study, the scores of the extent of staining
were evaluated according to the percentage of cells that
had positive immunoreactivity in every microscopic field
of view: 0, <25%; 1, 25%-50%; 2, 50%-75%; 3, 75%-100%.
The scores of IHC intensity ranging from 0 to 3
were determined as follows: 0, negative staining; 1, weak
staining; 2, moderate staining; 3, strong staining. By
multiplying the scores for extent and intensity, a total
score (range, 0 to 9) was achieved. PXN expression level
was considered high with scores of ≥ 4 and low with
scores of < 4.Cell transfection
For overexpression of endogenous PXN, the coding se-
quence of PXN was amplified and subcloned into the
pcDNA3.1 (+) vector (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’ instructions. AGS cells were
then transfected with a negative control vector or a PXN
expressing plasmid using lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA). To knockdown endogenous PXN ex-
pression in cells, small interfering RNA (siRNA) duplex
oligonucleotides targeting human PXN mRNA (si-PXN)
was obtained from Ribobio (Guangzhou, China). The tar-
geting sequences were: si-PXN#1: GCAGCAACCTTTCT
GAACT; si-PXN#2: GTGTGGAGCCTTCTTTGGT. In
the present study, we used si-PXN#1 as it could effectively
reduced endogenous PXN expression in our preliminary
experiments. The target sequence for scrambled siRNA
was 5′-GTCTCCACGCGCAGTACATTT-3′. SGC7901
cells were transfected with si-PXN or scramble siRNA ac-
cording to the manufacturer’s instructions.Cell proliferation assays
The 3-(4, 5-dimethylthiazole-2-yl)-2, 5-biphenyl tetrazo-
lium bromide (MTT) assay was performed to test cell
proliferation following a method as previously described
[24]. Cells were seeded in a 96-well plate at 1 × 103 cells/
well, the spectrophotometric absorbance was measured
for each sample at 490 nm, all the experiments were per-
formed in triplicate and repeated for 3 times, and the
average was calculated.
For the colony formation assay, cells (500/well) were
seeded in a six-well plate and cultured for 14 days at
37°C with 5% CO2 humidified air. Colonies were stained
with 0.1% crystal violet (1 mg/ml) and the numbers of
colonies containing more than 50 cells were counted.
The experiment was performed in triplicate and re-
peated for three times.In vitro cell migration assay
The cell migratory capacity was determined using trans-
well chambers (BD Biosciences) according to a method
previously described [25]. Briefly, cells (1 × 105/well)
were suspended in 100 μl serum-free medium and then
added to the upper chamber of the inserts, RPMI 1640
medium (GIBCO) containing 10% FBS (500 μl) was
added to the lower chamber as the chemotactic factor.
After culture for 22 hours, non-migrated cells on the
upper surface were removed gently with a cotton swab
and cells that migrated to the lower side of the depart-
ment were fixed and dyed with 0.1% crystal violet. The
numbers of migrated cells were calculated by counting
five different views under the microscopy. The experi-
ment was performed in triplicate and repeated for three
times.
Statistical analysis
All the data were presented as mean ± SD, a Student
t-test or Chi-square test was employed to compare the
differences as appropriate. Survival analysis was per-
formed using the Kaplan-Meier method and the log-
rank test. Multivariate analysis with Cox proportional
hazards model was used to investigate independent
prognostic factors. All P-values were two-sided, and a
P-value of < 0.05 was considered statistically significant.
Statistical analysis was performed by the SPSS software
package (version 16.0, SPSS Inc) or GraphPad prism 5.
Results
PXN is up-regulated in gastric cancer tissues and cell lines
The protein and mRNA level of PXN was evaluated in
gastric cancer tissues and cell lines. In paired primary
gastric cancer tissues and adjacent nontumorous tissues,
Western blot analysis revealed overexpression of PXN in
cancer tissues compared with adjacent nontumorous tis-
sues (Figure 1A). The level of PXN mRNA was increased
in 27 of 30 (P < 0.001) cancer tissues in comparison with
that of nontumorous tissues (Figure 1B). Moreover,
Western blot analysis showed the expression levels of
PXN were higher in gastric cancer cell lines than that of
normal gastric epithelial cell line GES-1 (Figure 1C).
Consistent with the level of protein, real-time PCR ana-
lysis confirmed PXN mRNA level was elevated in all five
gastric cancer cell lines (Figure 1D).
Overexpression of PXN is associated with adverse tumor
phenotype and poor prognosis in gastric cancer
We further investigated the expression of PXN in 239
paraffin-embedded gastric cancer tissues by IHC. As
shown in Figure 2, PXN protein was mainly located in the
cytoplasm of tumor cells. Positive staining was detected in
186 of 239 (77.8%) patients. One hundred and fifty-two
patients were possessed with low PXN expression while
Figure 1 PXN is up-regulated in gastric cancer tissues and cell lines. A, PXN protein expression levels in paired gastric cancer tissues and
adjacent nontumorous tissues (n = 8). B, PXN mRNA expression levels in 30 paired gastric cancer tissues and adjacent nontumorous tissue,
(P < 0.001). C, PXN protein levels in five gastric cancer cell lines and a normal gastric epithelial cell GES-1. D, PXN mRNA expression levels in
gastric cancer cell lines and a normal gastric mucosa cell line GES-1.
Figure 2 IHC analyses of PXN expression in gastric cancer tissues, the representative ones are shown. A, negative staining of PXN in
normal gastric mucosa; B, weak staining of PXN in well differentiated gastric cancer tissues; C, moderate staining of PXN in gastric cancer tissues;
D, strong staining of PXN in gastric cancer tissues, amplification (×200)
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on the IHC scores. The associations between PXN expres-
sion and clinical and pathologic parameters were summa-
rized in Table 1. High PXN expression was significantly
correlated with distant metastasis (P = 0.001), TNM stage
(P = 0.021) and survival status (P = 0.004). However, thereTable 1 Correlations between PXN expression and
clinicopathological characteristics in gastric cancer
patients
PXN expression






< 60 116 75(49.3) 41(47.1)
≥ 60 123 77(50.7) 46(52.9)
Gender 0.096
Male 177 118(77.6) 59(67.8)
Female 62 34(22.4) 28(32.2)
Tumor depth 0.527
T1 11 9(5.9) 2(2.3)
T2 29 20(13.2) 9(10.3)
T3 176 109(71.7) 67(77.0)
T4 23 14(9.2) 9(10.4)
Lymph node invasion 0.656
N0 55 35(23.0) 20(22.9)
N1 85 58(38.2) 27(31.0)
N2 64 39(25.6) 25(28.7)
N3 35 20(13.2) 15(17.4)
Distant metastasis 0.001a
M0 173 121(79.6) 52(59.7)
M1 66 31(20.4) 35(40.3)
Differentiation status 0.388
Well 99 68(44.7) 31(35.6)
Moderate 92 55(36.1) 37(42.5)
Poor and others 48 29(19.2) 19(21.9)
TNMb stage 0.021a
I 28 20(13.1) 8(9.1)
II 37 23(15.1) 14(16.1)
III 100 72(47.3) 28(32.2)
IV 74 37(24.5) 37(42.6)
Treatment 0.386
Surgery only 116 77(50.7) 39(44.8)
Surgery + chemotherapy 123 75(49.3) 48(55.2)
Survival status 0.004a
Alive 98 73(48.0) 25(28.7)
Dead 141 79(52.0) 62(71.3)
aP < 0.05, Chi-square test; bTNM: T, tumor; N, lymph node; M, distant metastasis.
Figure 3 The prognostic role of PXN in gastric cancer patients.
Kaplan-Meier analysis of overall survival based on PXN expression in
all 239 patients, patients with high PXN expression (n = 87)
possessed with significantly poor overall survival compared with that
of patients with low PXN expression (n = 152) (P < 0.001).was no association between PXN expression level and age,
gender, tumor depth, differentiation status and treatment.
Kaplan-Meier analysis with log-rank test was employed to
investigate the prognostic role of PXN for gastric cancer
patients. Patients with high PXN expression had signifi-
cantly worse overall survival than patient with low PXN
expression (Figure 3). In addition, Univariate analysis
revealed high PXN expression is a risk factor of death in
gastric cancer patients (HR = 2.05, 95%CI, 1.47-2.86; P <
0.001, Table 2). Besides, other factors including lymph
node invasion, distant metastasis and TNM stage were
also correlated with overall survival as demonstrated by
univariate analysis (Table 2). However, age, gender, differ-
entiation status, treatment and tumor depth were notTable 2 Univariate and Multivariate analysis of various
potential prognostic factors in gastric cancer patients
Factors Univariate analysis Multivariate analysis
HRb(95%CIc) P HRb(95%CIc) P
Age 1.27(0.91-1.77) 0.154 - -
Gender 1.11(0.76-1.61) 0.575 - -
Differentiation 1.42(0.98-2.06) 0.061 - -
Treatment 1.09(0.71-1.75) 0.456 - -
Tumor depth 1.32(1.08-1.60) 0.089 - -
Lymph node invasion 2.05(1.46-2.86) 0.005a 1.04(0.75-1.46) 0.803
Distant metastasis 2.74(1.89-3.98) <0.001a 2.51(1.58-3.99) <0.001a
TNM stage 1.64(1.22-2.13) <0.001a 1.32(0.91-1.93) 0.138
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indicated only distant metastasis and PXN expression
were independent prognostic factors for gastric cancer pa-
tients (P < 0.001 and P = 0.020, respectively, Table 2).
PXN promotes tumor growth and proliferation in vitro
We further investigated the role of PXN on the tumor
cell growth and proliferation through gain-of-function
and loss-of-function analysis. AGS cells were transfected
with pcDNA3.1(+)-PXN to overexpress PXN (Figure 4A).
The effects of PXN on cell growth and proliferationFigure 4 PXN promotes cell proliferation and colony formation in gas
of PXN in AGS cells and reduced after knockdown of PXN in SGC7901 cells
cells (P = 0.017) whereas knockdown of PXN inhibits cell proliferation in SG
expression of PXN stimulates colony formation in AGS cells (P = 0.026). F an
SGC7901 cells (P = 0.011).were then evaluated by MTT and colony formation as-
says. The results showed that ectopic expression of
PXN significantly promoted the viability of AGS cells
(Figure 4B, P = 0.017). The colony formation assay also
indicated the number of colonies was markedly in-
creased in PXN overexpressing cells compared with con-
trol cells (Figure 4D and E, P = 0.026). The impact of
PXN on cellular proliferation was further confirmed by
performing MTT and colony formation assays after PXN
knockdown in SGC7901 cells (Figure 4A). As indicated
in Figure 4C, F and G, compared with that of controltric cancer cells. A, PXN protein level is elevated after over-expression
. B and C, Ectopic expression of PXN promotes cell proliferation in AGS
C7901 cells as determined by MTT assays (P = 0.019). D and E, Ectopic
d G, Knockdown of PXN expression inhibits colony formation in
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growth rate and colony formation ability of SGC7901
cells (P = 0.019 and P = 0.011, respectively).
PXN promotes cell migration in vitro
As PXN expression is associated with distant metastasis in
gastric cancer patients, we then evaluated the potential
role of PXN on cellular migration by transwell assays.
AGS cells were transfected with PXN overexpressing or
control plasmid and seeded in the chamber, and their mi-
gratory abilities were determined 24 hours later. The
results showed ectopic expression of PXN significantly in-
creased the migratory capacity of AGS cells (Figure 5A
and B, P = 0.013). On the contrary, knockdown of
PXN dramatically reduced the migrated cell number of
SGC7901 (Figure 5C and D, P = 0.032).
Discussion
We have previously found that PXN is up-regulated in
colorectal cancer and associated with aggressive tumor
phenotypes [26]. However, the potential clinical and
pathologic role of PXN in gastric cancer is still un-
known. In this study, firstly, we detected the expression
of PXN in gastric cancer tissues and cell lines. The re-
sults showed that PXN was frequently up-regulated
in gastric cancer tissues and cell lines compared with
adjacent nontumorous tissues or normal gastric mucosa
cells. In addition, in a large cohort of gastric cancer pa-
tients, overexpression of PXN was significantly asso-
ciated with aggressive tumor characteristics, such asFigure 5 PXN promotes gastric cancer cell migration in vitro. A and B
demonstrated by transwell assays (P = 0.013). C and D, Knockdown of PXN
amplification (×100).distant metastasis and advanced TNM stage. Moreover,
high expression of PXN was correlated with poor overall
survival. Multivariate analysis demonstrated that PXN
expression was an independent prognostic factor for
gastric cancer patients. These results demonstrated that
overexpression of PXN was commonly observed in gas-
tric cancer. PXN might serve as an useful prognostic in-
dicator for patients.
Several studies have reported the clinical and patho-
logical significance of PXN in other tumor types. For ex-
ample, up-regulation of PXN is found in non-small cell
lung cancer [15] and prostate cancer [27]. Expression of
PXN is associated with adverse pathologic characteristics
in hepatocellular carcinoma [28]; PXN protein level is
correlated with advanced clinical stage and distant me-
tastasis in salivary adenoid cystic carcinoma [29]; ampli-
fication of PXN is frequently observed in high risk lung
cancer [17]. Our findings in gastric cancer are in lines
with these results. However, further studies are needed
to confirm the clinical role of PXN in gastric cancer.
PXN is a focal adhesion molecule that involved in sig-
naling transduction and cellular migration, it can increase
the adhesion between tumor cells and the surrounding
extracellular matrix and molecules, thereby promotes or
inhibits the tumor cell motilities. The effect of PXN on
cell spreading is mainly regulated by tyrosine/serine phos-
phorylation [30,31]. For instance, in breast cancer, cell mi-
gration and invasion stimulated by breast tumor kinase
(Brk) is mediated through PXN phosphorylation [32],
PXN is the substrate of Brk and functions as a “platform”, Ectopic expression of PXN promotes cell migration in AGS cells as
expression inhibits cell migration in SGC7901 cells (P = 0.032),
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sines 31 and 118 site is essential for pressure-induced cel-
lular metastasis and adhesion [33]. In this study, we found
that ectopic expression of PXN stimulated tumor prolifer-
ation and migration whereas knockdown of PXN sup-
pressed cellular growth and motility in gastric cancer cells.
Our results are similar to what observed in colorectal can-
cer, in which Jun et al. found that ectopic expression of
PXN could increase cell migration, invasion and adhesion
abilities whereas knockdown of PXN expression by small
interfering RNA suppressed these capacities [19]. Taken
together, these results suggest that PXN plays an import-
ant role in the growth and metastasis of gastric cancer.Conclusions
In conclusion, our study revealed a cell adhesion protein
PXN is frequently up-regulated in gastric cancer tissues
and cell lines. Overexpression of PXN is associated with
aggressive tumor phenotypes and adverse overall sur-
vival, thus implicating PXN might serve as an useful
prognostic indicator. Ectopic expression/knockdown of
PXN promotes/inhibits tumor growth and migration,
which indicates that PXN may play an important role in
the progression and metastasis of gastric cancer. How-
ever, further study is needed to investigate the under-
lying mechanism involved in PXN regulation in gastric
cancer.
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